Traders Buy High Volume of Call Options on Pfizer (NYSE:PFE)

Posted by Brenda Bartman on Nov 5th, 2026

Pfizer Inc. (NYSE:PFE – Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock investors purchased 673,000 call options on the company. This represents an increase of 584% compared to the typical volume of 98,364 call options.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Retirement Wealth Solutions LLC grew its position in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new position in Pfizer during the 2nd quarter worth about $26,000. Field & Main Bank purchased a new stake in Pfizer during the 2nd quarter worth approximately $27,000. Bullseye Investment Management LLC purchased a new position in Pfizer in the second quarter valued at $28,000. Finally, Timbuktu Capital Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE traded down $0.88 on Thursday, hitting $29.91. 39,283,221 shares of the stock traded hands, compared to its average volume of 39,801,063. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.44. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $170.46 billion, a PE ratio of 42.72, a P/E/G ratio of 2.04 and a beta of 0.31. The business has a fifty day moving average price of $28.69 and a two-hundred day moving average price of $26.86.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The firm had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the company earned $0.87 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. On average, research analysts predict that Pfizer will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. UBS Group boosted their target price on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. Argus set a $40.00 price target on shares of Pfizer in a research report on Wednesday. Scotiabank boosted their price objective on shares of Pfizer from $33.00 to $35.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. Finally, Guggenheim upped their price objective on shares of Pfizer from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $29.94.

Check Out Our Latest Report on Pfizer

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer raised its 2026 guidance to $62–$64 billion in revenue and adjusted EPS of $2.95–$3.05. In the third quarter, launched and acquired products grew 32% operationally, while non-COVID products grew 7%—supporting the company’s effort to diversify beyond pandemic products. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Some analysts raised their targets: Guggenheim moved to $33 and Scotiabank to $35, with both expressing bullish views. These targets signal potential upside if Pfizer delivers on its outlook. Guggenheim analyst update Scotiabank analyst update
Neutral Sentiment: Pfizer reported progress in a Phase 3 study of its monthly obesity drug. The program could provide a competitive opportunity, but the update does not establish clinical success or commercial prospects. Article: Pfizer Advances Monthly Obesity Drug Study
Neutral Sentiment: Analyst opinion remains mixed: Goldman Sachs maintained a Hold rating, while UBS and Citigroup raised their targets but kept Neutral ratings. Article: Goldman Sachs Remains a Hold on Pfizer
Negative Sentiment: Investors may be weighing margin compression and continuing weakness in pandemic-related products against the raised forecast. Pfizer’s growth and portfolio transformation still need to translate into durable results, leaving execution a key concern. Article: Pfizer Just Raised Guidance. The Bigger Test Comes Next

Pfizer Company Profile

(Get Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.